TorPharm

09/12/2016

Interesting news about Sumatriptan (Imitrex®)! Our scientists as part of the American Headache Society conducted research:
"A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults."

CONCLUSIONS:
"In healthy subjects, DFN-02, an intranasal spray containing 10 mg sumatriptan plus DDM, had a more rapid absorption profile than commercially available intranasal sumatriptan 20 mg, and systemic exposure from a single-dose administration of DFN-02 was similar to 4 mg SC sumatriptan and two-thirds that of 6 mg SC sumatriptan."
http://www.ncbi.nlm.nih.gov/pubmed/27613076 2016 Sep 10

Our R&D is already studying this area. Drug development wil takes a couple of years.

Perfect generic medications for the treatment of migraine!

09/10/2016

"Nowadays, only 50% of pharmaceutical enterprises are brand-makers. The expiration date of the patents for most of the medicine comes to the end one day. You know how hard it is to get a patent on something (even not speaking about FDA approval and billion dollars spent on all this bureaucratic fuss). So here comes a perfect time for many international pharmacies to enter the global market and go in for a race with generic copies of brand drugs. In Canada or India, it is a normal practice to start producing generics right after the drug’s brand version has got an approval from FDA at the US. Pharm companies have to compensate the huge amount of money to cover the cost for R&D, production, technique, and moreover the cost for design, marketing and promotion strategy. TorPharm, unlike brand companies, don’t invest their funds on advertising. And, this is the reason why generic medicine is much cheaper than a brand one "

09/10/2016

Nobel laureate James Watson visited Torpharm

The famous biologist James Watson is convinced - in 10 years, the majority of cancers will be completely curable. "Now, the most important thing - to seek a cure for advanced cancers," - said the Nobel laureate. CEO of Torpharm agrees with the discoverer of the DNA structure: "Our main task is to defeat the severe forms of cancer. For the development of our innovative products, we plan to bring in the tools of "artificial intelligence." Today there is no sense in copying the Western technology as the life cycle of innovation does not exceed 5 years. To become the first in the world, you must constantly be at the forefront of scientific advances, and create entirely new products. "
http://torpharm.com/about_us.html

09/10/2016

Our anthem is: “Generic drugs companies have tended to be viewed as followers. We want to be recognized as a leader.”

About Us